HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Congenital erythropoietic porphyria: a single-observer clinical study of 29 cases.

AbstractBACKGROUND:
Congenital erythropoietic porphyria (CEP) is an autosomal recessive cutaneous porphyria caused by decreased activity of uroporphyrinogen III synthase (UROS). Its predominant characteristics include bullous cutaneous photosensitivity to visible light from early infancy, progressive photomutilation and chronic haemolytic anaemia. Due to its rarity and genetic heterogeneity, clinical phenotypes are unclear and its impact on health-related quality of life (HRQoL) has not been previously assessed.
OBJECTIVES:
To define comprehensively CEP phenotypes and assess their impact on HRQoL, and to correlate these factors with laboratory parameters.
METHODS:
A single observer assessed patients with CEP from four European countries.
RESULTS:
Twenty-seven unrelated patients with CEP, aged between 7.6 and 65 years, participated in the study. The patients came from the U.K. (17), France (4), Switzerland (4) and Germany (2). Additional data were obtained for two deceased patients. Newly characterized features of CEP include acute-onset cutaneous and noncutaneous symptoms immediately following sunlight exposure, and pink erythematous facial papules. There was a lack of consistent genotype-phenotype correlation in CEP. The main poor prognostic factors in CEP are the early age of disease onset and haematological complications.
CONCLUSIONS:
CEP is a multisystem disease; cutaneous, ocular, oral and skeletal manifestations also contribute to disease severity and impact on HRQoL, in addition to the haematological complications. The rarity of the disease can lead to delayed diagnosis. The lack of consistent genotype-phenotype correlation in CEP suggests a contribution to phenotype from other factors, such as environment, patients' photoprotective behaviour and genes other than UROS. There is currently an unmet need for multidisciplinary management of patients with CEP.
AuthorsR P Katugampola, M N Badminton, A Y Finlay, S Whatley, J Woolf, N Mason, J C Deybach, H Puy, C Ged, H de Verneuil, S Hanneken, E Minder, X Schneider-Yin, A V Anstey
JournalThe British journal of dermatology (Br J Dermatol) Vol. 167 Issue 4 Pg. 901-13 (Oct 2012) ISSN: 1365-2133 [Electronic] England
PMID22816431 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Copyright© 2012 The Authors. BJD © 2012 British Association of Dermatologists.
Chemical References
  • Uroporphyrinogen III Synthetase
Topics
  • Adolescent
  • Adult
  • Child
  • Cohort Studies
  • Europe
  • Female
  • Genetic Association Studies
  • Humans
  • Male
  • Middle Aged
  • Porphyria, Erythropoietic (genetics, physiopathology)
  • Quality of Life
  • Uroporphyrinogen III Synthetase (genetics)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: